Journal list menu

What's new?

Socioeconomic status influences access to healthcare, impacting individuals' health and cancer risk. Here, the significance of socioeconomic status and income in cancer was investigated by comparing associations between individual- and area-level income and site-specific cancer incidence within a Canadian population. Incidence rates varied according to cancer site and income. Notably, incidence of digestive tract cancers, such as stomach and colorectal cancer, was elevated among individuals with low income, while melanoma, cancers of blood-forming tissues and breast and prostate cancer were more common among those with high income. The findings suggest that income predicts overall and site-specific cancer incidence in Canada.

What's new?

This study investigated the independent and joint associations of healthy lifestyle factors with mortality outcomes among cancer survivors by analyzing data from four prospective cohorts across three countries—the National Health and Nutrition Examination Survey and National Health Interview Survey in the United States, the UK Biobank and the Kailuan study in China. Adhering to a healthy lifestyle could reduce the risk of all-cause and cancer mortality by half among cancer survivors. Specifically, avoiding smoking and excessive alcohol consumption, maintaining a healthy diet, engaging in physical activity and maintaining a healthy body mass index were associated with improved prognosis.

What's new?

The first point of patient access to innovative medicines in Europe often occurs via early access programs (EAPs) or off-label use. Consideration of these factors, however, is mostly neglected in patient access evaluations. This study explored patient access to oncology medicines at the hospital level, with consideration of time, indications and context. Significant heterogeneity in time to access was observed between countries and hospitals. Specialized hospitals were likely to expedite access prior to reimbursement, and some countries were more likely to grant access via EAPs or off-label use. The findings highlight opportunities to improve access to oncology medicines across Europe.

What's new?

Socioeconomic factors influence individual cancer characteristics, as well as quality of cancer care and patient outcomes. Few studies on socioeconomic differences, however, have clearly described impacts specifically on prostate cancer care. Here, the authors investigated associations between aspects of care and education and household income among men with prostate cancer in Sweden. Analyses show that household income and education are significantly associated with use of pre-biopsy magnetic resonance imaging, primary treatment, sexual rehabilitation after surgery, and cause-specific mortality for high-risk non-metastatic prostate cancer. Covariate adjustments attenuated socioeconomic mortality gradients, suggesting that socioeconomic factors influence diagnostics more than later specialist prostate cancer care.

A novel health system reliability method has been developed and applied to cardio and cancer death rate data. Accurate disease multiregional prediction is done.

Gross platelet deficiency marks idiopathic thrombocytopenia's pathophysiology: normalization of the regulatory T cells (Tregs) through demethylation may well reverse the abnormal DNA methylation. Despite thrombopoietic receptor agonists’ recognized effectiveness, strongly demethylating (yet safe and affordable) ascorbate (e.g. with a plasma level of >1 mM several hours/week) could prevent their undesirable “rebound phenomenon” upon routine discontinuation, especially if abruptly mandated by refusal/adverse effects. [In Figure 1, star-shaped objects are platelets; Y-shaped objects are autoantibodies; in Figure 2, pro-inflammatory T helper 17 (Th17) cells are characterized by RORγt: a transcription factor (encoded by the gene Rorc) of the retinoic acid-receptor (RAR)-related orphan receptor (ROR) family. In ITP, Tregs expressing forkhead box P3 (Foxp3) are crucial for controlling ITP: in Figure 3, TET: ten-eleven translocation enzymes; 5mC; 5hmc: 5-hydroxymethylcytosine (the initiating step of active DNA demethylation. A cofactor fostering this process is vitamin C which acts synergistically with retinoic acid (RA)].

ON is a complex and multifactorial complication of Systemic Lupus Erythematosus (SLE). However, the pathophysiology and risk factors for ON in patients with SLE have not been fully determined yet. Here, we review the epidemiology, risk factors, diagnosis, and treatment options for glucocorticoid-induced ON, with a specific focus on patients with SLE

Inspired by the metastasis-seeding potential of VTT in ccRCC, we identified for the first time that pathological grading of VTT could serve as an unheeded prognostic factor. By incorporating VTT grading, TT-GPS score was constructed, displaying superior discriminatory ability for risk stratification in nonmetastatic ccRCC patients with VTT. This study highlights the significance of introducing VTT grading or TT-GPS score into routine pathological reports to improve the efficacy of risk assessment.

Immunogene therapy has become an effective and significant clinical strategy for cancer therapy. Enhancing the response rate to immunogene therapy is significant to controlling side effects and improving efficacy. Improved nonviral vectors combined with immunogene therapy efficiently deliver genes to the desired tumor cells and activate immune response to fight tumors while alleviating adverse reactions, which is a promising treatment approach for cancer.

A large majority of clinical trials demonstrate the promising results of the addition of immune checkpoint inhibitor (ICI) to the existing treatment strategy for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). Therefore, this article aims to discuss the results of these trials and to highlight the changes and future of ESCC treatment.

Human epidermal growth factor receptor 3 (HER3) overexpression represents a negative prognostic biomarker associated with poor survival. Targeting HER3 has shown some promise in early phase trials in both nonsmall cell lung cancer and metastatic breast cancer in heavily pretreated patients with varying degrees of response. Identifying a predictive biomarker will aid to better select patients that will respond to treatment.